Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Cannabis Bioscience International Holdings (CBIH) over the last 7 years, with Q3 2025 value amounting to 309.02%.

  • Cannabis Bioscience International Holdings' EBITDA Margin fell 2544600.0% to 309.02% in Q3 2025 from the same period last year, while for Aug 2025 it was 268.68%, marking a year-over-year decrease of 1611200.0%. This contributed to the annual value of 139.05% for FY2025, which is 563100.0% up from last year.
  • Per Cannabis Bioscience International Holdings' latest filing, its EBITDA Margin stood at 309.02% for Q3 2025, which was down 2544600.0% from 385.91% recorded in Q2 2025.
  • Cannabis Bioscience International Holdings' EBITDA Margin's 5-year high stood at 39.06% during Q2 2024, with a 5-year trough of 865.54% in Q1 2025.
  • For the 4-year period, Cannabis Bioscience International Holdings' EBITDA Margin averaged around 327.94%, with its median value being 275.89% (2023).
  • Per our database at Business Quant, Cannabis Bioscience International Holdings' EBITDA Margin soared by 5532400bps in 2024 and then plummeted by -4261900bps in 2025.
  • Over the past 4 years, Cannabis Bioscience International Holdings' EBITDA Margin (Quarter) stood at 222.34% in 2022, then skyrocketed by 33bps to 148.26% in 2023, then skyrocketed by 46bps to 80.31% in 2024, then plummeted by -285bps to 309.02% in 2025.
  • Its EBITDA Margin stands at 309.02% for Q3 2025, versus 385.91% for Q2 2025 and 865.54% for Q1 2025.